United Therapeutics Corporation
United Therapeutics Files for Preliminary Injunction in Patent Litigation Against Liquidia
Summary
On February 26, 2024, United Therapeutics Corporation filed a motion in the U.S. District Court for the District of Delaware for a preliminary injunction against Liquidia Technologies, Inc. The motion aims to prevent Liquidia from marketing its inhaled treprostinil product for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a use which United Therapeutics alleges infringes on its U.S. Patent No. 11,826,327. This litigation is part of a broader legal strategy by United Therapeutics to protect its intellectual property and market position in the treatment of PH-ILD.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement